Loading
A phase 1/2 trial of Rituximab and Ibrutinib in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL is a phase 1/2 interventional study registered as NCT04494503 by Ascentage Pharma Group Inc., with 123 participants planned, started 2020-08-31 and due to reach its primary completion in 2024-10-20. Interventions recorded: APG-2575, Rituximab and Ibrutinib.
Shares Ascentage Pharma, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.